Novo Nordisk shares fell 1.92% to $46.60 as investors weighed positive results from a pediatric obesity study against the early termination of two additional ziltivekimab trials. In the Phase 3 STEP Young study, 40.4% of children ages 6 to 12 receiving weekly semaglutide for 68 weeks reduced their BMI below obesity thresholds, compared with none in the placebo group. The cardiovascular trials in heart-failure patients were halted after an independent monitoring panel determined they had minimal prospects of producing different results from ziltivekimab's earlier failed late-stage study. In July, the drug did not reduce major adverse cardiovascular events versus placebo. One ziltivekimab trial in patients recovering from myocardial infarction remains active, with results expected in the first half of 2027.